CorMedix Inc. (NASDAQ:CRMD) Shares Sold by Sigma Planning Corp

Sigma Planning Corp trimmed its stake in shares of CorMedix Inc. (NASDAQ:CRMD) by 15.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,693 shares of the company’s stock after selling 6,254 shares during the period. Sigma Planning Corp owned about 0.06% of CorMedix worth $273,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of CRMD. Creative Planning acquired a new stake in shares of CorMedix during the 3rd quarter valued at approximately $129,000. Wealth Enhancement Advisory Services LLC raised its holdings in CorMedix by 10.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,184 shares of the company’s stock worth $422,000 after purchasing an additional 4,935 shares during the last quarter. Intech Investment Management LLC acquired a new position in CorMedix during the third quarter worth $119,000. FMR LLC raised its stake in shares of CorMedix by 54.3% during the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock worth $37,000 after buying an additional 1,625 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of CorMedix by 130.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company’s stock worth $97,000 after buying an additional 6,761 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Price Performance

NASDAQ:CRMD opened at $10.36 on Friday. The firm has a 50 day simple moving average of $10.35 and a 200-day simple moving average of $9.25. The firm has a market cap of $628.61 million, a PE ratio of -12.79 and a beta of 1.57. CorMedix Inc. has a 1-year low of $3.03 and a 1-year high of $13.85.

Analysts Set New Price Targets

CRMD has been the subject of a number of research reports. StockNews.com upgraded shares of CorMedix to a “sell” rating in a research report on Friday, November 8th. Royal Bank of Canada lifted their price objective on CorMedix from $11.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Finally, D. Boral Capital restated a “buy” rating and set a $15.00 price objective on shares of CorMedix in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.67.

CorMedix Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.